Parkinson's Disease

About Parkinson's Disease

IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD. There has been significant research over the past 50 years, resulting in important discoveries and treatments which provide relief.

PD specific regional MRI and PET analysis

  • IXICO work to provide Parkinson Disease specific volumetric image analysis endpoints using IXICO’s proprietary algorithms for MRI and PET.

Expert Nuclear Medicine Physicians

  • Team of expert Neuro-radiologists and Nuclear Medicine Physicians performing centralized, real time, standardised reads of PET and SPECT imaging for Parkinson’s Disease

Consultation and Supporting Regulatory Pathway

  • Protocol consultation at early stage to support Regulatory pathway.

Digital Biomarker Analysis

Combining the best emerging wearable technology together with our digital platform for analysis of biosensor data in Parkinson’s Disease.